# AUTHOR INDEX

## Volume 35, 1996


Abrams, R.A., 143
Abramson, D.H., 45
Acosta, R., 875
Adamietz, I.A., 61
Ahmad, N.R., 369
Alexander, A.A., 369
Alexander, E., III, 27, 493
Algan, Ö., 198, 925
Al-Sarraf, M., 425
Altun, M., 485
Amendola, B.E., 125
Anantha, N., 103
Anderson, B., 915
Anderson, L., 351
Ang, K.K., 455
Arcangeli, G., 609
Archer, G.E., 69
Arriagada, R., 519
Asai, Y., 587
Attal, P., 471
Auchter, R.M., 27
Ayan, İ., 485

Baillet, F., 305
Baldeyrou, P., 519
Bamberg, M., 779
Banerjee, A.K., 103
Bartelink, H., 417
Beckham, W.A., 765
Bel, A., 321
Belkacémi, Y., 53
Bellezza, D., 593
Benchimol, S., 1123
Ben-Josef, E., 197
Benson, A.B., III, 745
Berger, M.S., 541
Bergh, A., 885
Bernier, J., 649
Bigner, D.D., 69
Bilge, N., 1069
Binder, M., 875
Bjärngard, B.E., 161
Blach, L.E., 45
Bloomer, W.D., 849
Bobin, S., 471
Boente, M., 925
Boettcher, H.D., 61
Bohndorf, W., 293
Bojar, H., 137
Bolek, T.W., 687
Bortfeld, T., 721
Bosq, J., 471
Bourhis, J., 471
Brady, L.W., 125
Brennan, M.F., 351
Brenner, D.J., 629
Brenner, H.J., 807
Bretel, J.-J., 519
Brewer, Y., 343
Bristow, Robert G., 1123
Brown, B.W., 455
Brown, C., 875
Brown, F., 751
Brunelle, R., 875
Buatti, J.M., 27
Buchsbaum, D.J., 165
Burdette, E.C., 975
Burholt, D.R., 941
Burleson, W.D., 635
Burman, C., 721
Butler, E.B., 593

Calvo, F.A., 1075
Cameron, J.L., 143
Caplam, R.J., 197
Carducci, M.A., 143
Carol, M., 593
Carosella, E.D., 709
Carpenter, L.S., 593
Carter, D., 751
Casas, F., 1075
Cash, J., 875
Casper, E.S., 351
Cassisi, N.J., 443
Castiglione-Gertsch, M., 649
Cellini, N., 759
Chan, K.K., 993
Chandramouli, B.A.R., 103
Chang, L., 477
Chappell, R., 27, 907
Chauvet, B., 343
Chen, H.C., 133
Chen, J., 117
Chin, Y.Y., 133
Chinn, D.M., 869
Choi, I.-B., 95
Christie, D., 635
Chuba, P., 259
Chuba, P.J., 693
Chui, C.S., 721
Chyle, V., 281, 891
Clarke, M., 869
Clave, E., 709
Coco, C., 759
Cohen, J.I., 477
Coleman, C.N., 821
Collins, R.T., 299
Cooper, J.S., 425, 821
Cosset, B.P., 519
Court, W., 259
Cox, J.D., 197, 425
Creutzberg, C.L., 321
Cullip, T.J., 117
Curran, B.H., 579
Czerniak, B., 281

Daburon, F., 305
Daly, M.B., 669
Damber, J.-E., 885
D'Amico, A.V., 273
Dapper, F.D., 61
Das, B.S., 103
Das, S., 103
Dattoli, M., 875
Davis, C.S., 915
De Beukeleer, M., 771
de Geus, K., 151
Delanian, S., 305
Delattre, J.-Y., 527
Delclos, L., 891
del Regato, J.A., 5, 21
Deming, R.L., 299
Dendale, R., 471
Denekamp, J., 417
De Neve, W., 771
Denham, J.W., 197
DePotter, P., 125
De Santis, M., 759
Devi, S., 259
DeVol, E., 501
Domenico, D., 935
Doornbos, J.F., 915
Dräger, A.M., 507
Dubray, B., 709
Dubray, B.M., 1099
Duclos, M., 259, 693, 881
Dutreix, J., 227
Dwarakanath, B.S., 103

Efird, J., 439
Eggleston, W., 935
Ehrhardt, J.C., 915
Eisbruch, A., 377
Eisenberg, B.L., 669
Engler, M.J., 579
Epstein, B.E., 861
Eschwege, F., 631, 471
Etheridge, J., 875

Faillace-Akazawa, P., 1011
Fang, F.M., 133
Faure, C.F., 343
Fein, D.A., 669
Field, S.B., 731
Flentje, M., 1027
Flickinger, J.C., 185, 493
Flynn, S., 751
Folkes, A., 289
Fontenla, D.P., 173
Forastiere, A.A., 425
Forman, J.D., 259, 693, 881
Formenti, S.C., 993
Foroni, R., 565
Forsberg, F., 369
Fortin, A., 471
Fowble, B., 669
Fowler, J.F., 907
Fox, K.R., 661
Frank, A.R., 299
Frankel, K.A., 555
Freedman, G.M., 243
Friedman, W.A., 27
Frykholm, G.J., 1039
Fu, K.K., 425
Fuks, Z., 333, 415, 721
Fukui, T., 587

Galindo, R.A., 555
Galvin, J.M., 89
Garden, A.S., 455
Garg, P.K., 69
Gastorf, R.J., 599
Geara, F.B., 455
Gelber, R.D., 649
Gerosa, M., 565
Gershuny, A.R., 289
Gerweck, L.E., 81
Giacalone, S., 693
Gibbons, J.P., 605
Gildenberg, P., 593
Giri, G., 565
Glick, J.H., 661
Glimelius, B., 1039
Gluckman, E., 709
Goldhirsch, A., 649
Goldstein, L.J., 669
González, D.G., 731
Goodman, P., 731
Gorin, N.-C., 53
Graham-Pole, J., 687
Grant, W.H., III, 593
Gray, A.J., 501
Griffin, T.W., 541, 821
Grignon, D., 259
Grigsby, P., 847
Grochow, L.B., 143
Grossman, R., 593
Grunenwald, D., 519
Gutin, P.H., 37, 493

Haas, J.A., 661
Haffty, B.G., 679, 751
Hall, E.J., 629
Halligan, J.B., 541
Hamilton, C.S., 197
Hand, J.W., 731
Hanks, G.E., 198, 243, 251, 861
Hanlon, A., 925
Hanlon, A.L., 243, 251, 669, 861
Harling, O., 383
Harris, E.E.R., 661
Harris, J.R., 641
Harrison, L.B., 351
Hart, K., 259
Hart, K.B., 881
Hassounah, M., 501
Hatano, K., 357
Hayman, J., 827
Heilbronn, L.H., 555
Heilmann, H.-P., 207
Hellman, S., 15
Henk, J.M., 195
Hernandez, J.C., 125
Hess, C.F., 779
Hill, C., 471
Hill, R., 1123
Hliniak, A., 799
Hoch, J., 565
Hoffman, J.P., 669
Hogan, W.M., 925
Hogrefe, P., 635

Hogstrom, K.R., 599
Holland, J., 869, 1011
Holsti, L.R., 793
Holupka, E.J., 975
Hoppe, R.T., 821
Horowitz, M., 1003
Horton, J.L., 809
Høyer, M., 701
Hricak, H., 1011, 1113
Hruban, R.H., 143
Hruby, G., 635
Huijgens, P.C., 507
Hunt, M., 861
Hunt, M.A., 251
Hunter, N., 951
Hussey, D.H., 809, 915
Hyland, G., 299

Iannuzzi, C., 267
Ibanez, L., 1003
International Nasopharynx Cancer Study Group: VUMCA I Trial, 463
Irving, D., 935
Isacsson, U., 1039
Ishikawa, A., 549
Isobe, K., 357
Itami, J., 357
Ito, H., 357

Jacobs, J., 425
Jain, V., 103
Jamshed, A., 501
Janot, F., 471
Jeffers, S., 993
Jena, A., 103
Jennelle, R.L.S., 1035
Jensen, O.M., 701
Joseph, D., 649
Jovanovski, D., 1073
Jozsef, G., 993
Jung, B., 1039

Kalia, V.K., 103
Kandil, A., 289
Kandil, A.E., 501
Kannan, V., 103
Kaplan, E., 861
Kaplan, E.H., 745
Kaplan, I.D., 975
Kapoor, N., 103
Kapp, D.S., 189, 1117
Karlsson, U.L., 125
Katz, D., 383
Kaza, T., 197
Keller, J., 701
Khafaga, Y., 501
Khan, F.M., 605
Kiger, S., 383
Kim, R.Y., 1035
Kinsella, T.J., 27
Kiricuta, I.C., 293
Kirwan, N., 875
Kobayashi, K., 357
Kogelnik, H.D., 219
Kojima, T., 587
Kolotas, C., 137
Kondo, M., 357
Kondziolka, D., 185
Kondziolka, D.S., 493
Konski, A., 361, 847, 935
Kortmann, R.D., 779
Koval, J., 875
Kubo, A., 357
Kuhelj, J., 803
Kumar, R., 103
Kurtz, J.M., 623
Kusano, S., 587
Kutcher, G.J., 333, 415, 721

Lai, P.P., 173
Lamborn, K.R., 37
Lamond, J.P., 27
Lanciano, R.M., 925
Lane, B., 555
Laporte, J.-P., 53
Laramore, G.E., 425
Larson, D.A., 37, 493
Laugier, A., 53
Leavitt, D.D., 89
Lebesque, J.V., 321
Leblond, V., 53
Leborgne, F., 907
Leborgne, J.H., 907
Le Chevalier, T., 519
Lee, W.R., 243, 251, 861
Lefaix, J.-L., 305
Leibel, S.A., 333, 415, 721
Le Péchoux, C., 519
Leplat, J.-J., 305
Leung, S.W., 133
Levendag, P.C., 615
Levin, A.B., 27
Levy, L.B., 455
Levy, R.P., 555
Lichter, A.S., 377
Ling, C.C., 415, 721
Lipsitz, S.R., 745
Littrup, P., 259
Liu, F.-F., 731
Liu, J.-B., 369
Loeffler, J.S., 27, 493
Lonardi, S., 565
LoSasso, T., 721
Luboinski, B., 471
Lunsford, L.D., 493

Machin, D., 731
Mageras, G.S., 333
Magnotta, V.A., 915
Mailliard, J.A., 299
Malaise, E.P., 471
Malec, M.K., 37
Malfatti, C., 1011
Malpani, B.L., 535
Malyapa, R.S., 963
Mansour, E.G., 745
Marandas, P., 471
Marcial, V.A., 425
Marcus, R.B., Jr., 687
Markiewicz, D.A., 661
Markoe, A.M., 125
Marks, J., 369
Marks, M.P., 555
Marquez, C.M., 477
Martenson, J.A., 299, 745
Martin, M., 305
Martins, P., 439
Mason, K.A., 951
Mauch, P., 827
Maughan, R., 259
Maughan, R.L., 693
Mayr, N.A., 915
McCormick, B., 45, 843
McDermott, M.W., 37, 493
McLendon, R.E., 69
Medina, R., 1075
Mehta, K., 679
Mehta, M.P., 27
Meinass, H.J., 555
Meisner, C., 779
Melian, E., 333
Mendenhall, N.P., 687, 809
Mendenhall, W.M., 443
Meredith, R.F., 1035
Meyer, J.T., 1035
Meyn, R.E., 281
Milas, L., 951
Million, R.R., 443
Minsky, B., 351
Mirimanoff, R.-O., 623
Modig, H., 885
Moertel, C.G., 299
Mohan, R., 333, 721
Mohanti, B.K., 103
Montelius, A., 1039
Moore, R.L., 299
Morganti, A.G., 759
Morita, S., 549
Morrison, W.H., 599
Morrow, P.C., 993
Morton, R.F., 299
Moss, W.T., 477
Movsas, B., 861
Muggia, F.M., 993
Munzenrider, J.E., 809
Muthuswamy, M.S., 165
Mychalczak, B., 351

Nah, B.S., 95
Naida, J.D., 377
Nakano, T., 549
Nakfoor, B., 439
Neisler, J., 935
Nelson, D.F., 985
Nicolato, A., 565
Nielsen, O.S., 701
Nimrod, A., 305
Nordsmark, M., 701
Noyes, W.R., 27
Nygård, K., 1039

O'Brien, P., 197
Oetzel, D., 1027
O'Fallon, J.R., 299
Oh, W.Y., 95
Orton, C.G., 693
Osborn, J.L., 95
Otteman, L.A., 745
Overgaard, J., 701
Ozsahin, M., 53

Påhlman, L., 1039
Pajak, T.F., 197, 425
Palazzo, J.P., 369
Palisca, M., 785
Paljug, W.R., 941
Parsons, J.T., 443
Pasoli, A., 565
Pasqualin, A., 565
Patrice, S.J., 493
Pearse, H.D., 477
Pelsang, R.E., 915
Pène, F., 53
Peters, L.J., 455, 599
Petti, P.L., 1049
Phibbs, G., 935
Phillips, T.L., 37
Picciocchi, A., 759
Pickett, B., 1019
Pierquin, B., 227
Piovan, E., 565
Poisson, M., 527
Polizotto, S.L., 941
Pollack, A., 281, 407
Pollock, B.E., 493
Porter, A., 259
Prados, M.D., 37
Propert, K.J., 273
Prosnitz, L.R., 821
Purdy, J.A., 845

Raben, A., 351
Rath, G.K., 103
Raubertas, R.F., 985
Ravichandran, R., 103
Ravnihar, B., 803
Ray, S., 535
Reboul, F., 343
Redmond, E., II., 383
Reinfuss, M., 799
Reinstein, L., 721
Riley, K., 383
Rio, B., 53
Roach, M., III, 869, 1011, 1019
Roback, D.M., 605
Roberson, P.L., 165
Rodrigus, P.T.R., 321
Roncadin, M., 649
Roos, D.E., 765
Rose, C.M., 113, 809
Rosenman, J.G., 117
Rosskopf, B., 61
Rostom, A.Y., 289
Rostomily, R.C., 541
Roti Roti, J.L., 963
Rubin, P., 417, 985
Rudat, V., 1027
Ruffié, P., 519
Ruifrok, A.C.C., 951
Russo, A., 1003

Sahi, U.P., 103
Sailer, S.L., 117
Salter, M.M., 1035
Samuel, A.M., 535
Sanchez, S., 875
Sandhu, A., 985
Sandler, H.M., 377
Sapozink, M., 993
Sauer, J., 293
Scarborough, M.T., 687

Schell, M.C., 985
Schlienger, M., 53
Schmidberger, H., 779
Schmitt, G., 137
Schnabel, T., 137
Schoeppel, S.L., 377
Schraube, P., 1027
Schuchter, L.M., 745
Schulte, R.W.M., 555
Schultheiss, T.E., 251, 861
Schultz, C.J., 27, 187
Schultz, D.J., 661
Schuurhuis, G.J., 507
Schwaab, G., 471
Senan, S., 615
Shackford, H., 161
Shaer, A., 198
Shamsa, F., 259, 693, 881
Sharma, R., 259, 693
Sherar, M., 731
Shields, C.L., 125
Shields, J.A., 125
Shioda, A., 587
Shipley, W.U., 411, 1115
Shiu, A.S., 599
Shrieve, D.C., 493
Shrivastava, P.N., 993
Sichez, N., 527
Sigurdson, E.R., 669
Singh, A., 125
Skolyszewski, J., 799
Slater, J.D., 555
Slater, J.M., 555
Smickoska, S., 1073
Smith, A.A., 89
Sneed, P.K., 37, 493
Socié, G., 709
Solares, G., 383
Solin, L.J., 661
Soltys, M., 117
Song, C.W., 95
Sorace, R., 875
Sorosky, J.I., 915
Sowers, M., 361
Spence, A.M., 541
Spencer, S.A., 1035
Spirou, S., 721
Stattin, P., 885
Stein, D., 875
Steinberg, G.K., 555
Steinberg, M.L., 113
Stelzer, K.J., 541
Stephens, L.C., 281
Sternick, E.S., 579
Stevens, K.R., 477
Stock, R.G., 267
Stone, N.N., 267
Storme, G., 771
Stringer, S.P., 443
Stroom, J.C., 321
Sun, L.M., 133
Sun, W.M., 1003
Sunshine, J.H., 809, 851
Svensson, G.K., 975

Tabesh, T., 925
Tahir, S., 289
Takai, K., 587
Talamonti, M.S., 745
Taulelle, M., 343
Taylor, Y.C., 963
Ten Haken, R.K., 165
Terahara, A., 549
Terry, N.H.A., 281, 951
Teule, G.J.J., 507
Tewfik, H.H., 299
Thames, H.D., 951, 1099
Thomas, G.M., 413
Tokumitsu, H., 587
Touboul, E., 53
Tricaud, Y., 305
Tsai, J.-S., 579
Tsujii, H., 549
Tubiana, M., 227
Tucker, S.L., 455
Tung, S.S., 599
Turrisi, A.T., 377
Tyrkus, M., 935
Uematsu, M., 357, 587
Ulin, K., 785
Urias, R.E., 299
Uschold, G., 985

Valdagni, R., 609
Valentini, V., 759
van den Berg, J., 313
Van den Heuvel, F., 771
van der Giessen, P.-H., 399, 1059
van der Zee, J., 731
van Dieren, E.B., 507
van Dijk, J.D.P., 731
van Leeuwen-Stok, A.E., 507
van Putten, W.L.J., 731
van Rhoon, G.C., 731
van Rijn, J., 313
Vecchio, F.M., 759
Verellen, D., 771
Verhey, L., 1019
Vermey, J., 615
Vernon, C.C., 731
Vigliani, M.-C., 527
Vikram, B., 173
Vincent, P., 343
Visser, A.G., 321
Visser-Platier, A.W.J., 507
Vogt, H.-G., 137
von Lieven, H., 61
Vos, P.H., 321

Wagner, H., Jr., 745
Wallgren, A., 649
Wallner, K., 875
Wang, C.C., 439
Wang, C.J., 133
Wang, X.H., 721
Wannenmacher, M., 1027
Wara, W.M., 37, 493
Wasserman, S., 875
Watt, A., 151
Weaver, K.A., 37
Weeks, J., 827
Weil, M., 1019
Wen, B.-C., 915
Werner, A., 807
Werts, E.D., 941
Whaley, J.B., 731
Wharton, J.T., 891
Wheeler, J.A., 891, 915
White, R.A., 951
White, W.F., 289
Wibault, P., 471
Wilson, G., 471
Wintzer, A., 137
Withers, H.R., 633
Wong, G., 635
Woo, S.Y., 593
Wright, W.D., 963
Wu, Q., 721
Wynn, R., 985

Yamaguchi, Y., 357
Yann, V.M., 941
Yaparpalvi, R., 173
Yeo, C.J., 143
Yeoh, E., 1003
Yin, F.-F., 985
Yoshida, H., 357
Yu, L., 173
Yudelev, M., 259, 693
Yuh, W.T.C., 915

Zagars, G.K., 281, 407, 891
Zahurak, M.L., 143
Zaidi, S.T., 81
Zalutsky, M.R., 69
Zamboglou, N., 137
Zamenhof, R., 383
Zampieri, P., 565
Zavgorodni, S.F., 765
Zeidner, S., 935
Zelefsky, M., 415, 721
Zelefsky, M.J., 333
Zierhut, D., 1027
Zubizarreta, E., 907

# SUBJECT INDEX

## Volume 35, 1996


**A**

Abutting fields, 161
Accelerated hyperfractionated radiation therapy, 439
Acute adverse effects, 1039
Adenocarcinoma of the pancreas, 351
Adjuvant tamoxifen, 669
Adjuvant therapy, 143
Adverse effects, 299, 687
Alternative fractionation, 951
Anal cancer, 745
Anorectum, 1003
Antibodies, 165
Apoptosis, 281, 951
[$^{211}$At]Astatide, 69
Auger electrons, 507
Austria, 219
AVM, 565
AVMs, 555

**B**

$B6C3F_1$, 69
Backscattered electrons, 599
BALB/c, 69
Beam intensity modulated system, 593
Beam's eye view, 377
BID radiation therapy, 439
Bladder cancer, 281, 289
Bleomycin, 463
Bone marrow transplantation, 53
Boron, 383
Brachytherapy, 37, 267, 351, 549, 875, 891, 907, 925
Brain, 27
Brain neoplasms, 37
Breast cancer, 669, 679, 731
Breast conservation therapy, 661

**C**

Cancer of the cervix, 907
Capture, 383
Carcinoma of the breast, 173
Carcinoma of vagina, 891
Cataract incidence, 53
Cell cycle, 709
Cell death, 709
Cell proliferation, 701
Cerebral gliomas, 103
Cervical cancer, 915
Cervical carcinoma cell lines, 941
Charged particles, 1049
Chemotherapy, 477, 485, 661, 679
Childhood nasopharyngeal carcinoma, 485
Cisplatin, 343, 745
Cisplatin (BEC), 463
Clinical trials, 425
Clonogenic assay, 507
Collimator, 579
Collimator jaws, 605
Collimator scatter, 605
Colon cancer, 165
Color flow Doppler, 369
Combined modality, 425
Combined surgery and radiotherapy, 443
Compensator, 765
Compensators, 785
Complication probability, 1019
Computed tomography, 587
Computer graphics, 151
Computerized 3D treatment planning, 333
Computer simulation, 1099
Concomitant radiotherapy and chemotherapy, 519
Concurrent chemoradiotherapy, 343
Conformal neutron irradiation, 259
Conformal neutron/photon irradiation, 881
Conformal radiation therapy, 869, 975, 1027
Conformal therapy, 333
Conformal treatment, 861
Conservative surgery, 679, 751
Conservative surgery and radiation, 669
Contralateral breast dose, 173
Conventional linac-based radiosurgery system, 593
Cost benefit, 827
Cost effectiveness, 827
Cranio-spinal axis, 771
CT, 555, 1011
Cu/Zn–superoxide dismutase, 305
Cyclic AMP signal transduction, 313

**D**

Decision rules, 321
2-Deoxy-D-glucose, 103
Diodes, 173
Discipline, 793
DNA supercoiling, 963
Dose calculations, 1049
Dose distribution, 765
Dose escalation, 861
Dose, 181
volume histogram, 549
Dosimetry, 165, 383, 507, 875
Doubling time, 471
Downstaging, 281
Dynamic, 161
Dynamic radiotherapy, 771

**E**

Economic analyses, 827
Electron beams, 599, 765
Electron dosimetry, 785
Electronic portal imaging device (EPID), 985
Endometrial cancer, 361
Endometrial carcinoma, 935
Endoradiotherapy, 69
Epirubicin, 463
Epithermal, 383
Estrogen and progesterone receptor analysis, 935
Etoposide, 343
Ewing's sarcoma, 687
External beam radiation, 45
External pelvic irradiation, 925
Extracapsular cataract extraction, 53
Eye shields, 599

**F**

Failure patterns, 125
Fast-neutron radiation, 693
Fibrosis, 305
Field abutment, 765
Field matching, 161
Finland, 793
Flattening filter, 605
Flow cytometric DNA content analysis, 935
5-Fluorouracil, 745
Fractionated, 587
Fractionated irradiation, 81
Fractionation, 53, 477
Freund, L., 219

**G**

$^{67}$Gallium, 507
Gamma knife radiosurgery, 565
G-CSF, 61, 137
Gene expression, 709
Glioblastoma, 383
Glioblastoma multiforme, 37
Glioblastoma multiforme (GBM), 541
Gonadal dose, 399, 1059
Gynecological cancer, 1003

**H**

Head and neck cancer, 425, 455
Head and neck squamous cell carcinoma, 471
Head scatter, 605
Health care delivery, 113
Hemangioblastoma, 493
Hematopoietic stem cells, 709
Hemoglobin, 701
Heparin, 53
HER-2 neu, 751
Heritage, 793
Heterogeneity, 1099
High-grade astrocytomas, 541
High-risk endometrial cancer, 925
History, 793
History of radiotherapy, 219
Hodgkin's disease, 377
Holtzknecht, G., 219
Hyperfractionated radiotherapy, 519
Hyperthermia, 313, 731
Hypofractionation, 289

Hypopharyngeal neoplasms, 477
Hypoxia, 701

**I**

$^{125}$I, 37
$^{125}$I brachytherapy, 541
Image fusion, 975
Image processing, 151
Image registration, 117
Immunohistochemistry, 885
Immunophenotype, 709
Impotence, 869
*In vivo* dosimetry, 173
Inguinal lymph node, 133
Instantaneous dose rate, 53
Intellectual decline, 527
Intensity-modulated beams, 721
Intraocular lens implantation, 53
Intraperitoneal carboplatin, 993
Invasive thymoma, 357
Inverse technique, 721
$^{131}$Iodine-labeled monoclonal antibodies, 165
Ionizing radiation, 709
Irradiation, 679
Isocenter, 579
Isodose volumes, 565
Iterative target delineation, 555
IUdR labeling, 701

**K**

Kienböck, R., 219

**L**

Large-field radiotherapy, 137
Laryngeal carcinoma, 439
Late radiation effects, 305
Lead, 599
Leakage radiation, 399
Leukopenia, 61
Linear accelerator, 579, 587
Linear-quadratic model, 1099
Local excision, 759
Localization error, 377
Local recurrence, 751
Low pelvic tumor, 133
Lymph nodes, 679
Lymphoma, 377

**M**

Managed care environment, 113
Match-line, 161
Medical imaging, 151
Medium dose rate, 907
Medulloblastoma, 501
Melanoma, 383
Metastasis, 27
Mice, 69
Mn–superoxide dismutase, 305
Monte-Carlo, 383
Motility, 1003
MR imaging, 915
MRI, 555, 1011
mRNA, 709
Multifraction irradiation, 941
Multilead collimation, 721
Multileaf, 89
Multimodality imaging, 117, 555
Multiple scattering, 1049
Myelotoxicity, 137

**N**

Neoadjuvant hormonal therapy, 881
Neuropsychological follow-up, 527
Neutron, 383
Nonsmall cell, 343
Nonsmall cell lung cancer, 519
Normal tissue reactions, 455
Nuclear matrix proteins, 963

**O**

Observer study, 985
Olsalazine, 299
Oncogene-mediated radioresistance, 963
Oncology follow-up, 113
Optimization, 593
Organ motion, 333
Oropharyngeal carcinoma, 439
Oropharyngeal neoplasms, 477
Output factors, 605
Ovarian cancer, 993
Overall time, 951

**P**

p53, 885
Palladium, 875
Pancreatic neoplasm, 143
Paraaortic irradiation, 293
Pathology, 69
Patient positioning, 779
Patient positioning error, 1027
$^{103}$Pd, 351
Pelvic insufficiency fracture, 361
Pelvic radiation therapy, 299
Penumbra, 89
Percent of excretion, 535
Percent of uptake, 535
Peripheral dose, 399, 1059
$pO_2$, 701
Portal film, 985
Portal imaging, 321
Portal verification, 985
Posterior capsule opacification, 53
Potency, 267
Predictive assay, 701
Predictive assays, 81
Prognosis, 501
Prognostic factors, 273, 759, 891
Prognostic marker, 885
Prostate cancer, 243, 251, 259, 267, 273, 321, 861, 869, 881, 885, 975
Prostate cancer volume, 273
Prostate movement, 1027
Prostate radiotherapy, 333
Prostate-specific antigen, 243, 273
Prostatic carcinoma, 875
Protein Kinase A, 313
Protons, 555, 1049
Pulsed wave Doppler, 369

**Q**

Quality assurance, 579, 779
Quality of life, 869
Quantitative autoradiography, 165

**R**

R3230 AC tumor, 95
Radiation, 361, 369, 885
Radiation oncology, 793
Radiation resistance, 941
Radiation response, 941
Radiation therapy, 45, 173, 273, 357, 399, 587, 661, 745, 751, 779, 827, 891, 985, 1003, 1059
Radiation tolerance, 1019
Radiation treatment, 243
Radiobiological parameter ratios, 1099
Radioimmunotherapy, 165
Radioiodine therapy, 535
Radiolabeled antibodies, 165
Radionuclides, 165
Radiosensitivity, 81
Radiosurgery, 27, 493, 579
Radiotherapy, 37, 61, 103, 125, 133, 251, 281, 289, 293, 343, 377, 425, 477, 485, 493, 501, 527, 687, 701, 731, 759, 951, 1039, 1099
Radiotherapy dosage, 37, 687
Radiotherapy history, 803
Radiotherapy side effects, 693
Radiotoxicity, 507
Randomized trial, 731
Rat embryo cells, 963
Rectal cancer, 369
Rectal carcinoma, 1039
Rectal damage, 251
Rectal neoplasms, 759
Regional hyperthermia, 993
Repopulation, 951
Reproducibility, 81
Retinoblastoma, 45, 125
Review, 827
Risk assessment, 1059
RTOG, 425

**S**

Salivary gland carcinomas, 443
Salivary glands, 535
Scatter dose, 173
Scattering foils, 785
Schwarz, G., 219
Scientific visualization, 151
Second malignancy, 485
Seminoma, 293, 779
Setup accuracy, 321
Sexual dysfunction, 869
Sialogogue response, 535
Slovenia, 803
Small bowel, 1039
Soft tissue sarcoma, 701
Spheroids, 507

Sphincter preservation, 745
Stereotactic, 27, 587
Stereotactic radiosurgery, 555
Stereotactic radiosurgery treatment plan, 593
Stereotactic radiotherapy, 579
Stylization of structures, 151
Superficial x-ray beam, 765
Supratentorial gliomas, 527
Surgery, 357, 501
Surgical staging, 935
Survival, 69, 501, 885
Systemic administration, 69

**T**

$T_{pot}$, 951
$TCD_{50}$, 951
Technique, 125
Teletherapy, 891
Thermotolerance, 313
3D conformal radiotherapy, 1019
3D reconstruction, 565
3D treatment planning, 117, 1011
Three-dimensional, 377
Three-dimensional conformal radiation therapy, 251
Three-dimensional dose planning, 1039
Total body irradiation, 53, 701, 471
Transurethral resection, 885
Treatment gaps, 439
Treatment guidelines, 125
Treatment outcome, 477
Treatment planning, 377, 555
Treatment-planning, 383
Treatment techniques, 771
Treatment unit, 587
Tumor blood flow, 95
Tumor oxygenation, 701
Tumor regression, 915
Tumor response, 455
Tumor volume, 915
Tungsten, 599

**U**

U715, 507
Ultrasound, 975
Undifferentiated nasopharyngheal carcinoma, 463
Unresectable lung cancer, 519
Uterine cervix cancer, 549

**V**

Vascular thermal adaptation, 95
Verification films, 779

**W**

Wedge, 161

**Y**

Young men, 243